Literature DB >> 1478693

Lipopolysaccharide synergizes with tumour necrosis factor-alpha in cytotoxicity assays.

H Pfister1, T Hennet, T W Jungi.   

Abstract

Lipopolysaccharide (LPS) from Escherichia coli was found to synergize with human recombinant tumour necrosis factor-alpha (TNF-alpha) in the lysis of L929 and WEHI 164 (clone 13) murine fibroblasts, two cell lines classically used in TNF-alpha bioassays. The effect was noted with TNF-alpha at low (sublytic or lightly lytic) concentrations and was significant for LPS concentrations in the ng range. The LPS effect could be inhibited by polymyxin B, and was not observed when the TNF-alpha assay was performed in the absence of actinomycin D. Enhancement of TNF-alpha lysis by LPS occurred in several assays for determining TNF-alpha, including MTT cleavage, crystal violet staining and lactate dehydrogenase release. Synergism was obtained only when LPS and TNF-alpha were added to cells simultaneously, but not when applied in sequence. The reported synergism may be relevant for TNF-alpha determinations by bioassay, and for the understanding of pathophysiology of Gram-negative sepsis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478693      PMCID: PMC1421721     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

1.  Colorimetric measurement of lactic dehydrogenase activity of body fluids.

Authors:  P G CABAUD; F WROBLEWSKI
Journal:  Am J Clin Pathol       Date:  1958-09       Impact factor: 2.493

Review 2.  Assays for tumour necrosis factor and related cytokines.

Authors:  A Meager; H Leung; J Woolley
Journal:  J Immunol Methods       Date:  1989-01-06       Impact factor: 2.303

Review 3.  Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response.

Authors:  B Beutler; A Cerami
Journal:  Endocr Rev       Date:  1988-02       Impact factor: 19.871

4.  Increase of vulnerability to lymphotoxin in cells infected by vesicular stomatitis virus and its further augmentation by interferon.

Authors:  D Aderka; D Novick; T Hahn; D G Fischer; D Wallach
Journal:  Cell Immunol       Date:  1985-05       Impact factor: 4.868

5.  Synergistic stimulation of macrophage proliferation by the monokines tumor necrosis factor-alpha and colony-stimulating factor 1.

Authors:  D R Branch; A R Turner; L J Guilbert
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

6.  Tumour cell killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism.

Authors:  N Matthews; M L Neale; S K Jackson; J M Stark
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

7.  Studies on the in vitro biological activities of recombinant bovine tumor necrosis factor (rBoTNF) alpha. I. Synergistic antiviral efficacy of rBoTNF alpha, recombinant bovine interferon gamma (rBoIFN gamma) and their combination.

Authors:  M Campos; H B Ohmann; G Hughes; L A Babiuk; M J Lawman
Journal:  Antiviral Res       Date:  1988-11       Impact factor: 5.970

8.  Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism.

Authors:  P Suffys; R Beyaert; F Van Roy; W Fiers
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

9.  IGG-stimulated and LPS-stimulated monocytes elaborate transforming growth factor type beta (TGF-beta) in active form.

Authors:  L Schalch; C Rordorf-Adam; J R Dasch; T W Jungi
Journal:  Biochem Biophys Res Commun       Date:  1991-01-31       Impact factor: 3.575

10.  Shedding of tumor necrosis factor receptors by activated human neutrophils.

Authors:  F Porteu; C Nathan
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

View more
  9 in total

1.  Trimetazidine blocks store-operated Ca(2+) channels in HL-60 and THP-1 cell lines and inhibits the secretion of tumor necrosis factor.

Authors:  M G Vinokurov; E I Astashkin; M M Yurinskaya; M G Glezer; K E Sobolev; S V Grachev
Journal:  Dokl Biol Sci       Date:  2012-01-07

2.  Exogenous heat shock protein HSP70 suppresses bacterial pathogen-induced activation of human neutrophils.

Authors:  M M Yurinskaya; M B Evgen'ev; O Yu Antonova; M G Vinokurov
Journal:  Dokl Biochem Biophys       Date:  2010-12-24       Impact factor: 0.788

3.  The role of the TLR-dependent signaling pathway in the mechanism of phagocyte protection by exogenous heat shock protein HSP70 from the endotoxin action.

Authors:  O Yu Antonova; M M Yurinskaya; M B Evgen'ev; M G Vinokurov
Journal:  Dokl Biol Sci       Date:  2013-10-23

4.  Exogenous heat shock protein HSP70 protects human blood phagocytes at the action of different chemotypes of lipopolysaccharide.

Authors:  O Yu Antonova; M M Yurinskaya; M B Evgen'ev; A V Suslikov; M G Vinokurov
Journal:  Dokl Biol Sci       Date:  2013-01-06

5.  Bioassay for tumor necrosis factors-alpha and -beta.

Authors:  T J Evans
Journal:  Mol Biotechnol       Date:  2000-07       Impact factor: 2.695

6.  Recombinant human Hsp70 protects against lipoteichoic acid-induced inflammation manifestations at the cellular and organismal levels.

Authors:  Maxim Vinokurov; Vladimir Ostrov; Marina Yurinskaya; David Garbuz; Arkady Murashev; Olga Antonova; Mikhail Evgen'ev
Journal:  Cell Stress Chaperones       Date:  2011-08-16       Impact factor: 3.667

7.  Encapsulated Hsp70 decreases endotoxin-induced production of ROS and TNFα in human phagocytes.

Authors:  M M Yurinskaya; O Yu Kochetkova; L I Shabarchina; O Yu Antonova; A V Suslikov; M B Evgen'ev; M G Vinokurov
Journal:  Cell Stress Chaperones       Date:  2016-10-26       Impact factor: 3.667

8.  The relationship between uterine pathogen growth density and ovarian function in the postpartum dairy cow.

Authors:  E J Williams; D P Fischer; D E Noakes; G C W England; A Rycroft; H Dobson; I M Sheldon
Journal:  Theriogenology       Date:  2007-06-15       Impact factor: 2.740

9.  Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro.

Authors:  T W Jungi; R Miserez; M Brcic; H Pfister
Journal:  Experientia       Date:  1994-02-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.